Human Molecular Genetics, 2003, Vol. 12, No. 6 617-624
© 2003 Oxford University Press
Transgenic rat model of Huntington's disease


1Department of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany, 2Department of Molecular Human Genetics, University of Bochum, Bochum, Germany, 3Department of Medical Genetics, Children's Hospital, University of Rostock, Rostock, Germany, 4Department of Medical Genetics, University of Tübingen, Tübingen, Germany, 5Department of Cardiology, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany, 6Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany, 7Department of Non-invasive Imaging, Leibniz Institute for Neurobiology, Magdeburg, Germany, 8Department of Pharmacology, University of Tartu, Tartu, Estonia, 9Department of Neurology, University of Tübingen, Tübingen, Germany, 10Institute of Pharmacology and Toxicology, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany, 11Institute of Medical Genetics, University of Wales, College of Medicine, Cardiff, UK, 12Department of Neurology, University of Ulm, Ulm, Germany, 13Institute of Medicine, Research Center, Jülich, Germany and 14Department of Human Genetics, Emory University School of Medicine, Atlanta, CA, USA
Received October 24, 2002; Accepted January 4, 2003
Huntington's disease (HD) is a late manifesting neurodegenerative disorder in humans caused by an expansion of a CAG trinucleotide repeat of more than 39 units in a gene of unknown function. Several mouse models have been reported which show rapid progression of a phenotype leading to death within 35 months (transgenic models) resembling the rare juvenile course of HD (Westphal variant) or which do not present with any symptoms (knock-in mice). Owing to the small size of the brain, mice are not suitable for repetitive in vivo imaging studies. Also, rapid progression of the disease in the transgenic models limits their usefulness for neurotransplantation. We therefore generated a rat model transgenic of HD, which carries a truncated huntingtin cDNA fragment with 51 CAG repeats under control of the native rat huntingtin promoter. This is the first transgenic rat model of a neurodegenerative disorder of the brain. These rats exhibit adult-onset neurological phenotypes with reduced anxiety, cognitive impairments, and slowly progressive motor dysfunction as well as typical histopathological alterations in the form of neuronal nuclear inclusions in the brain. As in HD patients, in vivo imaging demonstrates striatal shrinkage in magnetic resonance images and a reduced brain glucose metabolism in high-resolution fluor-deoxy-glucose positron emission tomography studies. This model allows longitudinal in vivo imaging studies and is therefore ideally suited for the evaluation of novel therapeutic approaches such as neurotransplantation.
* To whom correspondence should be addressed at: Department of Functional and Applied Anatomy, OE 4120, Hannover Medical School, Carl Neuberg Str. 1, 30625 Hannover, Germany. Tel: +49 5115322868; Fax: +49 5115328868; Email: hoersten.stephan.von{at}mh-hannover.de
Present address: Department of Neurology, University of Bonn, Bonn, Germany.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Y. Dai, N. L. Dudek, Q. Li, S. C. Fowler, and N. A. Muma Striatal Expression of a Calmodulin Fragment Improved Motor Function, Weight Loss, and Neuropathology in the R6/2 Mouse Model of Huntington's Disease J. Neurosci., September 16, 2009; 29(37): 11550 - 11559. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Pouladi, R. K. Graham, J. M. Karasinska, Y. Xie, R. D. Santos, A. Petersen, and M. R. Hayden Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin Brain, April 1, 2009; 132(4): 919 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. N. Gellerich, Z. Gizatullina, H. P. Nguyen, S. Trumbeckaite, S. Vielhaber, E. Seppet, S. Zierz, B. Landwehrmeyer, O. Riess, S. von Horsten, et al. Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca2+ in Transgenic Huntington Disease Rats J. Biol. Chem., November 7, 2008; 283(45): 30715 - 30724. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Bode, M. Stephan, H. Suhling, R. Pabst, R. H. Straub, K. A. Raber, M. Bonin, H. P. Nguyen, O. Riess, A. Bauer, et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17{beta}-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males Hum. Mol. Genet., September 1, 2008; 17(17): 2595 - 2609. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Strand, Z. C. Baquet, A. K. Aragaki, P. Holmans, L. Yang, C. Cleren, M. F. Beal, L. Jones, C. Kooperberg, J. M. Olson, et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration J. Neurosci., October 24, 2007; 27(43): 11758 - 11768. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cyr, T. D. Sotnikova, R. R. Gainetdinov, and M. G. Caron Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin FASEB J, December 1, 2006; 20(14): 2541 - 2543. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Nguyen, P. Kobbe, H. Rahne, T. Worpel, B. Jager, M. Stephan, R. Pabst, C. Holzmann, O. Riess, H. Korr, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease Hum. Mol. Genet., November 1, 2006; 15(21): 3177 - 3194. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Atsuta, H. Watanabe, M. Ito, H. Banno, K. Suzuki, M. Katsuno, F. Tanaka, A. Tamakoshi, and G. Sobue Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients Brain, June 1, 2006; 129(6): 1446 - 1455. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Van Raamsdonk, J. Pearson, D. A. Rogers, N. Bissada, A. W. Vogl, M. R. Hayden, and B. R. Leavitt Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease Hum. Mol. Genet., May 15, 2005; 14(10): 1379 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Van Raamsdonk, J. Pearson, E. J. Slow, S. M. Hossain, B. R. Leavitt, and M. R. Hayden Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease J. Neurosci., April 20, 2005; 25(16): 4169 - 4180. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Karl, S. Lin, C. Schwarzer, A. Sainsbury, M. Couzens, W. Wittmann, D. Boey, S. von Horsten, and H. Herzog Y1 receptors regulate aggressive behavior by modulating serotonin pathways PNAS, August 24, 2004; 101(34): 12742 - 12747. [Abstract] [Full Text] [PDF] |
||||
![]() |
S-M Pulst Neurogenetics: single gene disorders J. Neurol. Neurosurg. Psychiatry, December 1, 2003; 74(12): 1608 - 1614. [Abstract] [Full Text] [PDF] |
||||






